Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Biogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.
Read the full article on the original site.
Read Full Article